The American kratom industry, a market now valued at over $1.5 billion, finds itself at a volatile crossroads as internal factions and federal regulators square off over the emergence of ultra-potent extracts. A decade after a grassroots movement successfully blocked a federal ban on the kratom plant, a new substance derived from it—7-hydroxymitragynine, commonly known as 7-OH—has sparked a civil war among advocates and prompted calls for emergency scheduling by the United States government. This conflict pits traditional kratom lobbyists, who view 7-OH as a threat to the plant’s legal status, against a burgeoning sector of extract manufacturers who argue that these concentrated compounds are the future of natural pain management.
The Evolution of Kratom: From Traditional Leaf to Potent Extract
Kratom (Mitragyna speciosa), a tropical evergreen tree native to Southeast Asia, has been used for centuries by laborers and traditional healers for its stimulant and opioid-like effects. In the United States, the substance gained mainstream traction in the early 2010s as an alternative to prescription opioids. The primary psychoactive alkaloid in the leaf is mitragynine, which typically accounts for the majority of the plant’s alkaloid content. However, 7-hydroxymitragynine (7-OH), though present only in trace amounts in the raw leaf, is significantly more potent.
While traditional kratom consumption involves brewing tea or ingesting dried leaf powder, the modern marketplace has seen a shift toward highly concentrated products. Through chemical manipulation and extraction processes, manufacturers have isolated 7-OH, creating gummies, tablets, and liquid "shots" that deliver doses far exceeding what could be consumed through natural leaf material. This technological leap has transformed kratom from a niche botanical into a mass-marketed commodity found in gas stations and convenience stores nationwide.
A History of Regulatory Resistance and Industry Growth
The current tension is rooted in a pivotal moment in 2016, when the Drug Enforcement Administration (DEA) announced its intent to place kratom into Schedule I of the Controlled Substances Act, the same category as heroin and LSD. The DEA cited an "imminent hazard to public safety," but the proposal met with unprecedented backlash. A bipartisan coalition of lawmakers, including Senator Bernie Sanders and then-Representative Rand Paul, joined thousands of consumers in a campaign to protect the plant.
The success of this campaign led to a period of rapid, largely unregulated growth. By 2024, estimates suggest that between 15 and 20 million Americans consume kratom regularly. Proponents argued that kratom served as a "DIY off-ramp" for those struggling with fentanyl and oxycodone addiction, providing a natural alternative with a lower risk of fatal respiratory depression. However, the emergence of 7-OH has complicated this narrative, leading the very organizations that once defended the plant to now call for a ban on its most potent derivatives.
The Scientific and Safety Debate Surrounding 7-OH
The primary point of contention between the two sides of the industry involves the pharmacological profile of 7-OH. Mac Haddow, the senior public policy fellow at the American Kratom Association (AKA), has become one of the most vocal critics of the extract. The AKA, which represents the interests of traditional kratom sellers, argues that 7-OH products are "chemically manipulated, full-blown opioids" that masquerade as natural botanicals.
Research indicates that 7-OH is a potent mu-opioid receptor agonist. While it is derived from the kratom plant, its biological impact at high concentrations is poorly understood. Chris McCurdy, a leading kratom researcher and director of the University of Florida’s translational drug development core, has expressed concerns regarding the purity and safety of these products. Many 7-OH items on the market contain unknown compounds with no history of human or animal testing, leading to a "wild west" environment where consumers are effectively serving as test subjects.
Reports of adverse effects have increased alongside the popularity of 7-OH. Consumers have reported excruciating withdrawal symptoms, including severe anxiety, chills, and physical pain, which some claim are more intense than those associated with traditional kratom powder. On platforms like Reddit, communities such as "Quittingfeelfree" have grown to thousands of members, where users share stories of becoming unwittingly addicted to kratom-based energy drinks and extracts.
The Political Landscape: RFK Jr., Trump, and the MAHA Dilemma
The regulation of 7-OH has become an unexpectedly prominent issue within the executive branch. Last July, Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. labeled the 7-OH industry "sinister," specifically criticizing the marketing of these products in candy-flavored gummy forms that could appeal to children. This sentiment was echoed by FDA Commissioner Marty Makary, who urged the DEA to categorize 7-OH as a Schedule I substance to prevent "the next wave of the opioid crisis."
The political situation is further complicated by the "Make America Healthy Again" (MAHA) movement and the personal ties of high-ranking officials. Markwayne Mullin, the Secretary of Homeland Security, has been scrutinized for a reported investment of up to $1 million in Botanic Tonics, the parent company of the popular kratom drink "Feel Free." Despite Mullin’s public stance in favor of cracking down on synthetic substances, his financial link to a major player in the kratom market has raised questions about potential conflicts of interest.
President Donald Trump added to the confusion in May 2024 with remarks from the Oval Office publicly endorsing "natural 7-OH." Analysts suggest these comments likely referred to the kratom plant itself rather than the concentrated extracts, but the statement highlighted the lack of clarity regarding the substance at the highest levels of government.
Chronology of the 7-OH Regulatory Crackdown
The movement to restrict 7-OH has moved faster at the state level than at the federal level. The following timeline outlines the escalating regulatory pressure:
- 2016: The DEA fails to ban kratom after public and political outcry.
- 2019-2022: 7-OH extracts begin appearing in gas stations and specialty shops.
- May 2023: Federal agents seize 250,000 bottles of "Feel Free" and other kratom products, worth over $3 million, citing inadequate safety information.
- July 2024: HHS Secretary RFK Jr. and the FDA issue formal warnings against 7-OH, labeling it a public health threat.
- Late 2024 – Early 2025: A dozen states, including California, Vermont, and Ohio, implement individual bans or strict regulations on synthetic or highly concentrated 7-OH products.
- April 2025: Colorado legislators debate the "Daniel Bregger Act," aiming to establish a regulatory framework for kratom and its alkaloids.
- June 2025: The National Institutes of Health (NIH) clears the way for a landmark trial to study mitragynine as a treatment for opioid use disorder.
The Industry Response: Regulation vs. Prohibition
The 7-HOPE Alliance, an advocacy group representing 7-OH manufacturers, argues that prohibition is the wrong approach. Michele Ross, the group’s chief scientific adviser, maintains that 7-OH is an inherent part of the kratom plant and that separating it is scientifically illogical. "To say 7-OH is not kratom is to say caffeine is not coffee," Ross testified to Colorado lawmakers.
The alliance advocates for "responsible regulation" rather than a total ban. This would include standardized labeling, age restrictions, and potency limits. Jackie Subeck, executive director of the 7-HOPE Alliance, warns that a federal ban would not eliminate demand but would instead push consumers toward an unregulated black market, increasing the risk of contamination and overdose.
Conversely, entrepreneurs like Soren Shade of Top Tree Herbs argue that while the molecule itself shouldn’t be criminalized, the "bad actors" in the industry must be held accountable. Shade compares the calls for a ban to "banning cars because one manufacturer cheated on emissions tests." He suggests that the focus should be on punishing companies that use deceptive marketing and lack quality control rather than banning the substance entirely.
Broader Implications and the Future of Research
The potential classification of 7-OH as a Schedule I drug carries significant implications for the scientific community. Researchers like McCurdy argue that such a designation would "cripple" the ability to study the compound’s potential benefits. Some early evidence suggests that 7-OH, if used correctly, could offer a safer profile than traditional prescription opioids because it does not recruit beta-arrestin, a protein associated with the lethal respiratory depression caused by drugs like morphine and fentanyl.
If the federal government moves forward with a ban, it may trigger a "whack-a-mole" scenario. Already, some manufacturers are pivoting to semi-synthetic derivatives such as MGM-15 and pseudoindoxyl, which are even more potent and less understood than 7-OH.
As the Trump administration continues to issue executive orders regarding drug policy, the fate of 7-OH remains uncertain. The drug represents a complex challenge for the "natural wellness" movement: it is a substance derived from nature that possesses the potency of a laboratory-engineered pharmaceutical. Whether it will be remembered as a breakthrough in pain management or the catalyst for a new phase of the opioid epidemic depends on the regulatory path chosen in the coming months. For now, the industry remains deeply divided, while millions of consumers wait to see if their access to these potent extracts will remain legal or be relegated to the shadows of the underground market.
